- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Budenheim 
Captisol 
Clariant 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IamFluidics 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma 
All4Nutra
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Budenheim Captisol Clariant Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IamFluidics IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma - All4Nutra
Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product
Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product
Cabergoline is a dopamine agonist with applications as anti-Parkinson drug and prolactin inhibitor. The cabergoline drug product Laktostop® 50 µg/mL is used in veterinary medicine for lactation suppression in cats and dogs e.g. during false pregnancy. Recently, during ongoing HPLC stability testing of Laktostop® 50 µg/mL a new oxidation product of Cabergoline was identified. A synthesis starting from Cabergoline was developed, followed by full characterization of the unknown impurity.
Highlights
- Synthesis and isolation of an oxidation product starting from cabergoline.
- Identity was demonstrated by HPLC experiments and high-resolution mass spectrometry.
- Structure elucidation by MS-MS fragmentation experiments and 1D/2D NMR analysis.
- Radical induced formation mechanism is proposed.
Preliminary HPLC and LC-MS analyses indicated the unknown impurity as mono-oxygenated product of Cabergoline (Cabergoline N-oxide) that is presumably formed with oxygen by a radical mechanism. Thus, Cabergoline was treated with oxidizing agents such as m-chloroperoxybenzoic acid to afford the desired Cabergoline-N-oxide as a byproduct. After isolation by column chromatography, NMR and LC-MS-MS studies provided evidence that oxidation occurred at the N-allyl nitrogen of Cabergoline to form Cabergoline-N-oxide.
Read more here
Degradant enrichment experiments in the drug substance and drug product
The drug product Laktostop® 50 µg/mL consists of the active ingredient cabergoline and the liquid excipient miglyol – a mixture of saturated medium-chain triglycerides, mainly composed of capric acid or caprylic acid molecules and glycerol. To elucidate the formation of the impurity in LAK different attempts were conducted. Initially, a cabergoline solution 50 µg/mL was freshly prepared and analyzed.
Tilman Lechel, Ruben Silva Otero, Andreas Springer, Anja Rutkowski, Dominik Matzkow, Johannes Zart, Tobias Hartmann, Dieter Hochhuth, Identification and structural elucidation of an oxidation product generated during stability studies of Cabergoline drug product, Journal of Pharmaceutical and Biomedical Analysis, Volume 248, 2024, 116282, ISSN 0731-7085, https://doi.org/10.1016/j.jpba.2024.116282.
